Twentyeight-Seven Therapeutics launches with $65m to develop RNA-modulating cancer therapies
In an ambitious move within the biotechnology sector, a new U.S. biotech company, Twentyeight-Seven Therapeutics (28-7), has been established in Cambridge with a primary focus on developing therapies for cancer and other diseases by modulating non-coding RNA (ncRNA). Coinciding with its launch, Twentyeight-Seven Therapeutics announced a successful $65 million Series A financing round led by […]